Risk Stratification and Workup of Microhematuria

Confirmation and Initial Assessment

A urine dipstick showing 3+ RBCs must be confirmed by microscopic urinalysis demonstrating ≥ 3 RBCs per high‑power field on a properly collected, non‑contaminated specimen before any urologic evaluation is initiated (American Urological Association/Society of Urologic Female (AUA/SUFU) guideline) 1.
Proceeding with urologic workup on dipstick results alone is discouraged; microscopic confirmation is required to avoid unnecessary referrals and costs 2, 3.

Prior to imaging or cystoscopy, clinicians should rule out common benign sources of hematuria: urinary‑tract infection (obtain urine culture before antibiotics), recent menstruation, vigorous exercise, recent urologic procedure or trauma, and renal parenchymal disease (evaluate for proteinuria, casts, and elevated creatinine) 4.
Anticoagulation therapy does not exempt patients from the full hematuria workup; the same diagnostic pathway applies 3, 4.

Low/Negligible Risk – Women < 60 years without additional risk factors have a 0 % cancer risk; no further urologic evaluation is required 1.
Intermediate Risk – Patients with microhematuria plus one or more risk factors (e.g., age ≥ 60 years in women, age > 35 years in men, smoking history, occupational chemical exposure) have an estimated 3.1 % cancer risk and should receive imaging and cystoscopy 1.
High Risk – Overall cancer risk ≈ 6.3 % (rising to 10.9 % when gross hematuria is present). High‑risk criteria include:
- Age ≥ 60 years in women or > 35 years in men 1, 3, 4
- Documented smoking exposure (pack‑years) 1
- Occupational exposure to carcinogenic chemicals 4
- Gross (visible) hematuria, which carries a 30‑40 % malignancy risk 4
- History of pelvic irradiation 3
- Chronic urinary‑tract infection or indwelling foreign body 4
- Irritative voiding symptoms 3
- Prior analgesic abuse or chemotherapy exposure 3, 4
Among high‑risk patients, the presence of gross hematuria yields a four‑fold higher cancer detection rate (10.9 % vs 2.6 % for isolated microhematuria) 1.

Obtain a detailed smoking history (including all tobacco products) and document pack‑years; provide evidence‑based cessation resources as part of the workup 1.
Measure blood pressure and perform a focused genitourinary exam (pelvic exam in women, digital rectal exam in men) 1, 3, 4.
Consider interstitial cystitis in women presenting with chronic pelvic pain and microhematuria after other causes have been excluded 3, 4.

CT urography is the preferred imaging modality for intermediate‑ and high‑risk patients, offering thin‑slice, multiplanar reconstruction of both upper and lower urinary tracts 2, 1.
MR urography is an acceptable alternative when CT is contraindicated (e.g., renal insufficiency, contrast allergy, pregnancy) 3, 4.
Validation data show that nearly 70 % of malignancies identified in women with microhematuria originated in the renal (upper‑tract) system, underscoring the need for comprehensive imaging 1.

Cystoscopy is required for all intermediate‑ and high‑risk patients in addition to imaging, because imaging alone may miss bladder lesions, particularly flat urothelial carcinoma 2, 3, 1.

Over‑evaluation of young women (< 60 years without risk factors) is unnecessary; their cancer risk is essentially zero 1.
Anticoagulation does not justify omission of the standard workup 3, 4.
Malignancies can occur even with low‑grade microhematuria (3‑10 RBCs/HPF); 12 of 13 cancers in a validation cohort were detected in this range, reinforcing the importance of risk‑based evaluation 1.